Cargando…

Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)

PURPOSE: This study aimed to assess efficacy and safety of anlotinib as a first- or second-line treatment for advanced or metastatic hepatocellular carcinoma (aHCC) and to identify the predictive plasma cytokines on efficacy of anlotinib. METHODS: It was a phase II clinical study. Patients with aHCC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Yongkun, Zhou, Aiping, Zhang, Wen, Jiang, Zhichao, Chen, Bo, Zhao, Jianjun, Li, Zhiyu, Wang, Liming, Bi, Xinyu, Zhao, Hong, Liu, Kan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286948/ https://www.ncbi.nlm.nih.gov/pubmed/33826043 http://dx.doi.org/10.1007/s12072-021-10171-0

Ejemplares similares

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
por: Raynaud, C., et al.
Publicado: (2015)

The role of KIR2DL3/HLA-C*0802 in Brazilian patients with rheumatoid vasculitis
por: Nishimura, Wester Eidi, et al.
Publicado: (2015)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis
por: Zhou, Jun, et al.
Publicado: (2023)

Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial
por: Zhu, Jun, et al.
Publicado: (2021)

Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)
por: Han, Chun, et al.
Publicado: (2021)

Variants Identified by Hepatocellular Carcinoma and Chronic Hepatitis B Virus Infection Susceptibility GWAS Associated with Survival in HBV-Related Hepatocellular Carcinoma
por: Li, Cong, et al.
Publicado: (2014)

CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study
por: Liu, Zhujun, et al.
Publicado: (2018)

A nomogram to predict prognosis after surgery for young patients with hepatocellular carcinoma
por: Li, Xingchen, et al.
Publicado: (2021)

Prognosis of patients with hepatocellular carcinoma and hypersplenism after surgery: a single-center experience from the People’s Republic of China
por: Li, Cong, et al.
Publicado: (2014)

Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a systematic review
por: Wei, Zhewen, et al.
Publicado: (2022)

Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study
por: Guo, Wenbo, et al.
Publicado: (2020)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Bronchial Fistula: Rare Complication of Treatment with Anlotinib
por: DENG, Pengbo, et al.
Publicado: (2020)

Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study
por: Jiang, Zhichao, et al.
Publicado: (2022)

Neoadjuvant Anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma: Short-term results of an open-label, randomized, phase II trial
por: Wang, Ying-Jian, et al.
Publicado: (2022)

Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity
por: Hu, Ting, et al.
Publicado: (2020)

Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial
por: Xu, Bushu, et al.
Publicado: (2023)

OA08.02. Differential acute effects of real and sham acupuncture on mu-opioid receptor availability in treatment naive and conditioned chronic pain patients
por: Akbar, N, et al.
Publicado: (2012)

Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo
por: Ji, Yurou, et al.
Publicado: (2022)

A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma
por: Li, Qingqing, et al.
Publicado: (2022)

Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study
por: Zou, Hanhui, et al.
Publicado: (2022)

Comparison of S‐1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single‐center retrospective study
por: Jiang, Zhichao, et al.
Publicado: (2020)

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
por: Hu, Nanlin, et al.
Publicado: (2021)

Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study
por: Zhao, Jingzhu, et al.
Publicado: (2022)

Different Algicidal Modes of the Two Bacteria Aeromonas bestiarum HYD0802-MK36 and Pseudomonas syringae KACC10292(T) against Harmful Cyanobacteria Microcystis aeruginosa
por: Park, Bum Soo, et al.
Publicado: (2022)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
por: Zhang, Xi, et al.
Publicado: (2021)

Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China
por: Chen, Xiao-Qi, et al.
Publicado: (2022)

Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
por: Zhang, Wen, et al.
Publicado: (2022)

Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma
por: Luo, Mei, et al.
Publicado: (2021)

Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG08.02) randomized clinical trial
por: Song, Andrew J, et al.
Publicado: (2021)

S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial
por: Du, Feng, et al.
Publicado: (2015)

TACE combined with portal particle implantation in a case of stage IIIa primary hepatocellular carcinoma treated with sequential anlotinib
por: Lin, Cheng, et al.
Publicado: (2023)

Prognostic significance of the preoperative alkaline phosphatase‑to‑albumin ratio in patients with hepatocellular carcinoma after hepatic resection
por: Wang, Yikai, et al.
Publicado: (2023)

Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial
por: Song, Andrew J, et al.
Publicado: (2022)

The addition of anlotinib reduces the incidence of radiation and immunotherapy-induced pneumonia
por: Yang, Linlin, et al.
Publicado: (2023)

A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer
por: Wu, Di, et al.
Publicado: (2020)

Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study
por: Chen, Yongbiao, et al.
Publicado: (2023)

Antitumor effects of anlotinib in thyroid cancer
por: Ruan, Xianhui, et al.
Publicado: (2018)

Hypertensive Retinopathy Secondary to Anlotinib Treatment
por: Zhang, Xiaohua, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3pg3018n7597gnp3da7fdtak2s